Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 18/20 | 0.60 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308048 | 1.00 | DGAT1 (0.60) | DGAT1CSGALNACT1LCK | |
| SCHEMBL2308884 | 1.00 | DGAT1 (0.60) | DGAT1CSGALNACT1LCK | |
| SCHEMBL1748125 | 0.89 | DGAT1 (0.64) | DGAT1CSGALNACT1LCK | |
| SCHEMBL1748124 | 0.89 | DGAT1 (0.64) | DGAT1CSGALNACT1LCK | |
| SCHEMBL1748123 | 0.89 | DGAT1 (0.64) | DGAT1CSGALNACT1LCK | |
| SCHEMBL6032263 | 0.89 | DGAT1 (0.64) | DGAT1CSGALNACT1LCK | |
| Bicarbonate SCHEMBL2314968 | 0.86 | DGAT1 (0.44) | DGAT1CSGALNACT1LCK | |
| SCHEMBL12430212 | 0.85 | DGAT1 (0.80) | DGAT1CSGALNACT1 | |
| SCHEMBL2306708 | 0.85 | DGAT1 (0.64) | DGAT1CSGALNACT1 | |
| SCHEMBL2308770 | 0.85 | DGAT1 (0.64) | DGAT1CSGALNACT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | claimed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | claimed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | claimed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | claimed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | claimed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | DGAT1 34/4885CSGALNACT1 1245/4885LCK 3833/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | DGAT1 34/4885CSGALNACT1 1245/4885LCK 3833/4885 |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | DGAT1 34/4885CSGALNACT1 1245/4885LCK 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.